{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
sulfisoxazole acetyl
to a specific field?
Status:
Possibly Marketed Outside US
Source:
NCT04702776: Phase 4 Interventional Completed Dry Eye
(2021)
Source URL:
First approved in 1997
Source:
NaturVet ArthriSoothe by The Garmon Corporation
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
First approved in 1984
Source:
NADA136383
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
ANDA211796
(1955)
Source URL:
First approved in 1955
Source:
ANDA211796
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
First approved in 1950
Source:
NDA007073
Source URL:
Class:
POLYMER
Cellacefate is a commonly used polymer phthalate in the formulation of pharmaceuticals, such as the enteric coating of tablets or capsules and for controlled release formulations. Cellacefate's use in enteric coatings allows tablets to remain intact in the unfavorable gastric acid secretion of the stomach, but dissolve in the more basic areas of the duodenum, thus protecting the stomach from ulceration or allowing greater absorption form the duodenum. Cellacefate is a reaction product of phthalic anhydride and a partial acetate ester of cellulose.
Status:
Possibly Marketed Outside US
Source:
Canada:MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP C
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT01586338: Phase 4 Interventional Completed Osteoarthritis
(2012)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Canada:MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP W-135
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Canada:MENINGOCOCCAL POLYSACCHARIDE ANTIGEN GROUP Y
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT04669119: Phase 4 Interventional Unknown status Breast Cancer Female
(2020)
Source URL:
First approved in 1985
Source:
21 CFR 348
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT03222401: Phase 2 Interventional Terminated Neisseria Gonorrhoeae
(2017)
Source URL:
Class:
CONCEPT
